Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247354 | 0.83 | MAOB (0.36) | MAPTSMN1; SMN2RAB9ANPC1MAOB | |
| SCHEMBL25944824 | 0.70 | SMN1; SMN2 (0.45) | SMN1; SMN2RAB9ANPC1HPGDKDM4E | |
| SCHEMBL248007 | 0.68 | CYP1A2 (0.46) | MAPTSMN1; SMN2KDM4EKMT2AKDR | |
| SCHEMBL542159 | 0.67 | DAO (0.65) | MAPTSMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL10518552 | 0.67 | KEAP1 (0.69) | SMN1; SMN2RAB9ANPC1MAOBCA12 | |
| SCHEMBL3144090 | 0.67 | KDM4E (0.55) | MAPTSMN1; SMN2RAB9AHPGDKDM4E | |
| SCHEMBL23151886 | 0.66 | MAPT (0.47) | MAPTSMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL246790 | 0.66 | — | — | |
| SCHEMBL31139879 | 0.64 | MAPT (0.46) | MAPTSMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL9407745 | 0.64 | RAB9A (0.46) | MAPTSMN1; SMN2RAB9ANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759371-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759371-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759371-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2588468-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2588468-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2588468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130085151-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085151-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085151-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2012003262-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003262-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085151-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | MAPT 3420/4885SMN1; SMN2 909/4885RAB9A 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.